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of infected individuals, and chronic hepatitis C (CHC) can lead to
cirrhosis and hepatocellular carcinoma. The innate immune sys-
tem is central to host-virus interactions during the entire natural
course of the disease. The HCV NS3/4A protease efﬁciently
cleaves and inactivates two important signaling molecules in
the sensory pathways that react to HCV pathogen-
associated molecular patterns (PAMPs) to induce interferons
(IFNs), i.e., mitochondrial antiviral signaling protein (MAVS) and
Toll-IL-1 receptor domain-containing adaptor inducing IFN-b
(TRIF). Despite this viral escape mechanism, the innate immune
system strongly reacts to HCV within the ﬁrst days after infec-
tion. The sensory pathways, the type(s) of IFNs involved and
the cellular source of IFNs are largely unknown. After 4–8 weeks,
HCV speciﬁc T cells are recruited to the liver. IFN-c-stimulated
genes get strongly expressed in the liver. In about 30% of patients,
the virus is eliminated during the acute phase of the infection by
T cell-mediated antiviral mechanisms. In the remaining 70% of
patients, HCV persists for decades. During this phase, T cell-
derived IFN-c cannot be detected any more in liver biopsies.
Instead, in about half of the patients, hundreds of type I or III
IFN-stimulated genes become again strongly expressed. However,
this innate immune reaction is ineffective against HCV. Moreover,
patients with constitutive IFN-stimulated gene (ISG) expression
have a poor response to treatment with pegylated IFN-a (Peg-
IFN-a) and ribavirin. The viral escape mechanisms that protect
HCV from IFN-mediated innate immune reactions are not entirely
understood, but might involve blockade of ISG protein translationJournal of Hepatology 20
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43 kDa.refractory IFN signal transduction pathways or to cell compart-
ments that are not accessible to antiviral IFN-stimulated effector
systems. Recently, genetic variations near the IL28B (IFN-k3) were
found to be strongly associated with spontaneous clearance of
HCV and response to treatment with PegIFN-a and ribavirin.
The ﬁnding supports a central role of the innate immune
response in host-viral interactions. The signaling pathways that
link genetic variants of IL28B with immune answers to HCV
remain to be elucidated. The present review article attempts to
summarize current knowledge of some central aspects of the
interactions of HCV with the innate immune system.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatitis C virus
Hepatitis C virus (HCV) infects 130–170 million persons world-
wide [1]. HCV is parenterally transmitted, mainly due to injection
drug use and unsafe transfusions and therapeutic injections [2].
Acute HCV infections (AHC) are often oligo- or asymptomatic
[3]. In 70–80% of those infected, the virus persists and the infec-
tion becomes chronic. Spontaneous clearance of HCV is rare in
the chronic phase of the infection. In most patients, chronic hep-
atitis C (CHC) leads to some degree of liver ﬁbrosis, and in 15–25%
of patients, cirrhosis develops after 10–40 years [4]. Patients with
CHC and cirrhosis are at increased risk of liver failure and hepa-
tocellular carcinoma development [5].
HCV is a positive-strand enveloped RNA virus belonging to the
family Flaviviridae. HCV isolates are classiﬁed into 6 major geno-
types (numbered from 1 to 6) that differ in the sequence of the
9.6 kb genome by 30–35% [6]. Within genotypes, subtypes (desig-
nated with small letters, e.g., 1a, 1b) differ in their sequence by
20–25%. HCV infects humans and chimpanzees. Hepatocytes are
the main target cells of HCV. Virus entry into hepatocytes requires
multiple cellular factors including scavenger receptor type B1 (SR-
B1), CD81, claudin-1, and occludin [7]. Reliable and widely repro-
ducible methods to detect viral RNA or proteins in liver samples of
infected patients are lacking. It is therefore still a matter of contro-
versy what percentage of hepatocytes is simultaneously infected
at any given time point during acute and chronic infection with13 vol. 58 j 564–574
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Fig. 1. IFN signaling through the Jak-STAT pathway. Type I (IFN-as and IFN-b) and type III (IFN-ks) IFNs bind to distinct receptors, but activate the same downstream
signaling events, and induce almost identical sets of genes mainly through the activation of IFN-stimulated gene factor 3 (ISGF3) and STAT1 homodimers. IFN-c (the only
type II IFN) activates STAT1, but not ISGF3, and induces a partially overlapping but distinct set of genes. Adapted from Ref. [116], with permission from Elsevier.
JOURNAL OF HEPATOLOGYHCV. The HCV RNA is translated at ribosomes into a long precursor
polyprotein that is then cleaved by cellular and viral proteases
into the mature viral proteins [8]. Inhibitors of the viral NS3/4A
protease are used for therapy of HCV genotype 1 infections
[9,10]. HCV replication occurs in the cytoplasm in speciﬁc mem-
brane alterations named the membranous web [8]. Replication
is very dynamic: an estimated 1012 virions are produced and
cleared per day in an infected individual [11].
Innate immunity and interferons
Innate immune responses are the ﬁrst line of defense against
viral infections and interferons (IFNs) are the central cytokines
responsible for the induction of an antiviral state in cells and
for the activation and regulation of the cellular components of
innate immunity such as natural killer (NK) cells [12]. Type I IFNs
(comprising several IFN-a and one IFN-b) and type III IFNs (IFN-
k1, -k2, and -k3; also designated IL29, IL28A, and IL28B) are pro-
duced by cells infected with viruses and by key sentinel cells of
the innate immune system: macrophages and dendritic cells
(DCs). Type II IFN (IFN-c) is produced by NK and natural killer
T (NKT) cells as part of the innate immune response, and by anti-
gen-speciﬁc T cells (both CD4+ Th1 and CD8+ cytotoxic T
lymphocytes).
Two important pathways that detect viral genomes and
induce type I and type III IFNs have been discovered and charac-
terized during recent years: the toll-like receptor (TLR) depen-
dent pathway [13,14] and the cytosolic pathway triggered by
binding of viral RNA to the RNA helicases retinoic acid inducible
gene-I (RIG-I) and melanoma differentiation antigen 5 (MDA5)
[15,16]. TLRs are a family of transmembrane pattern recognitionJournal of Hepatology 201receptors that recognize microbial pathogen-associated molecu-
lar patterns (PAMPs) and activate the expression of genes
involved in inﬂammatory and immune responses [14]. There
are at least 10 human TLRs, and 3 of them are involved in the rec-
ognition of viral infections: TLR3, TLR7, and TLR9. TLRs are
expressed on various immune cells such as macrophages, den-
dritic cells (DCs), B cells, but also on ﬁbroblasts and epithelial
cells. While TLRs involved in the recognition of bacterial compo-
nents are expressed on the cell surface, TLR3, TLR7, and TLR9 are
localized in intracellular compartments such as endosomes. TLR3
recognizes double-stranded RNA [17], TLR7 detects single-
stranded RNA [18,19] and TLR9 interacts with unmethylated
DNA with CpG motifs [20]. TLR3 activation induces signaling cas-
cades that mainly involve adapter molecules Toll-IL-1 receptor
domain-containing adaptor inducing IFN-b (TRIF) and the kinase
TBK1. TLR7 and TLR9 signal through MyD88 and the IRAK4-
IRAK1-IKKa kinase cascade [21]. Both pathways converge on
the activation of the key transcription factors NF-jB and inter-
feron regulatory factor (IRF) 3 and 7. Importantly, macrophages
and DCs do not have to be infected by viruses in order to produce
IFNs. Instead, they constantly sample material from the outside,
including virus containing remnants of apoptotic cells and intact
viral particles. Degradation processes in the endosomes then
expose viral nucleic acids to recognition by TLRs.
Viruses that avoid the endosomal entry pathway can be
detected by the cytosolic pathways of type I and III IFN induction.
These signaling pathways are initiated by the recognition of viral
50 triphosphate RNA and double-stranded RNA by RIG-I and
MDA5. Binding of viral RNA induces a conformational change of
these sensors that results in the binding to mitochondrial
antiviral signaling protein (MAVS, also designated Cardif, VISA,3 vol. 58 j 564–574 565
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Fig. 2. Natural course of HCV infection. In the early phase of acute infection (the
ﬁrst 4–8 weeks), HCV induces a type I or III IFN response that restricts viral
replication (green box). With the recruitment of HCV speciﬁc T cells in the late
phase of AHC, the gene expression proﬁle in the liver switches to an IFN-c pattern
(blue box). In late AHC, viral replication is strongly inhibited, and in about 30% of
the patients, HCV is completely eliminated. In 70% of the cases, HCV persists and
can induce again a type I or III IFN response in about half of the patients (upper
green box). The other patients have little to no activation of ISGs in the liver
(empty box). Changes in serum HCV load (red), alanine aminotransferase levels
(ALT) (blue) and IFN-stimulated gene expression (top bar) are shown. The dashed
line shows the upper limit of normal for ALT. Adapted from Ref. [116], with
permission from Elsevier.
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IPS-1), an essential downstream adaptor in the cytosolic pathway
[22–25]. Through as yet unidentiﬁed mediators, MAVS then prop-
agates the signal to the TBK1 and IKKi (IKKe) or the IKKa and
IKKb kinases that ﬁnally activate the transcription factors IRF3
and NF-jB, respectively. Activated IRF3 and NF-jB bind to
response elements in the promoters of type I and III IFN genes.
All types of IFNs induce an antiviral state by the transcrip-
tional activation of hundreds of genes. The speciﬁc set of genes
differs between IFNs and target cell type. In general, IFN-as and
IFN-ks induce a largely overlapping set of genes in cells that
express receptors for both IFN-a and IFN-k [26], whereas the
IFN-c-induced gene set is more distinct [27,28]. The number of
genes regulated by IFNs also differs between cells. For instance,
pegylated IFN-a signiﬁcantly induces 200 to 300 genes in the
liver, but nearly 2000 genes in peripheral blood mononuclear
cells (PBMCs) [29].
Type I and II IFNs are essential for the defense against virus.
Knock-out mice that lack the receptors for IFN-a or IFN-c, or
components of the IFN signal transduction pathway succumb to
otherwise harmless viruses [30,31], and infants with genetic
defects of the IFN system die from viral infections despite best
medical care [32]. Type III IFNs have a more restricted role, most
likely in viral defense at epithelial surfaces in the respiratory and
gastro-intestinal tract.
Interferon signal transduction
IFN-as and IFN-b bind to the ubiquitously expressed IFN-a recep-
tor (IFNAR). IFN-ks bind to a different receptor consisting of the
ubiquitously expressed IL-10R2 chain (shared with the IL-10
receptor) and a unique IFN-k receptor chain whose expression
is mainly restricted to epithelial cells [33,34]. IFN-c binds to
the widely expressed IFN-c receptor (IFNGR). All IFN receptors
connect to the Jak-STAT pathway to transmit signals from the cell
surface to the nucleus. Binding of IFNs to their cognate receptors
activates members of the Janus kinase family that then phosphor-
ylate tyrosine residues located on the intracellular receptor
domains [35]. STATs are recruited to phosphorylated receptors
through their SH2 domains, and a highly speciﬁc and selective
interaction that determines speciﬁcity in Jak-STAT signaling
[36]. Because of the presence of speciﬁc docking sites at their
receptors, IFN-as, IFN-b, and IFN-ks mainly activate signal trans-
ducer and activator of transcription (STAT) 1 and STAT2, whereas
IFN-c activates only STAT1. All IFNs induce STAT1 homodimers
that bind to gamma activated sequence (GAS) elements in IFN-
stimulated genes (ISGs). Type I and III IFNs additionally induce
the heterotrimeric transcription factor IFN-stimulated gene factor
3 (ISGF3) that consists of STAT1, STAT2, and IRF9 and binds to
IFN-stimulated response elements (ISRE) [35,37,38] (Fig. 1).
IFN signaling is controlled by a number of negative regulators
such as SOCS, USP18, PIAS, and TcPTP. Suppressor of Cytokine
Signaling (SOCS) proteins are important negative regulators of
Jak-STAT signaling that are rapidly induced and provide an early
negative feedback loop [39]. SOCS1 deﬁcient mice develop severe
inﬂammatory disease [40], but are very resistant to viral infec-
tions, most likely because of enhanced type I IFN signaling [41].
Ubiquitin speciﬁc peptidase 18 (USP18, also designated
UBP43) is another important negative regulator in type I IFN
signaling [42,43]. USP18/UBP43 was originally identiﬁed as a
protease cleaving ubiquitin-like modiﬁer interferon-stimulated
gene 15 (ISG15) from target proteins [44]. Similar to ubiquitina-566 Journal of Hepatology 201tion, conjugation of ISG15 to target proteins (ISGylation) occurs
through sequential enzymatic action of activating E1, conjugat-
ing E2, and ligating E3 enzymes [45]. ISGylation modulates sig-
nal transduction pathways and proteins involved in immunity
and stress responses [46,47]. IFN-induced ISGylation has an
important protective role against several viruses (e.g., inﬂuenza
and herpes simplex) [48,49]. HCV seems to be an exception.
ISGylation actually promotes HCV FL-J6/JFH virus production
in HuH7.5 cells [50]. Since ISG15 also conjugates to STAT1, the
negative regulatory role of USP18 on IFN signaling was origi-
nally attributed to its cysteine protease enzymatic activity.
However, an active site cysteine mutant USP18 was found to
inhibit IFN signaling as well, demonstrating that USP18 nega-
tively regulates IFN-a signaling independently of its ISG15-
deconjugating ability [51]. Indeed, USP18 was reported to inhi-
bit the activation of Jak1 by interfering with its interaction with
IFNAR2 [51]. USP18 deﬁcient mice show a severe phenotype
characterized by brain cell injury, poly-I:C hypersensitivity,
and premature death [52,53]. Interestingly, they are resistant
to otherwise fatal cerebral infections with lymphocytic chorio-
meningitis virus and vesicular stomatitis virus [54]. USP18 is a
key mediator of refractoriness of liver cells to continuous stim-
ulation with IFN-a [55]. USP18 is not induced by IFN-c, and
does not inhibit IFN-c or IFN-k signaling [56].
Protein inhibitors of activated STAT1 (PIAS1) and PIAS3 specif-
ically bind to tyrosine phosphorylated STAT1 and STAT3, respec-
tively, and inhibit the DNA-binding of STAT dimers [57]. PIAS1
selectively inhibits interferon-inducible genes and is important
in innate immunity. As a consequence, PIAS1 deﬁcient mice show
increased protection against pathogenic infection [58].3 vol. 58 j 564–574
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Host-virus interactions in acute hepatitis C
Prospective studies with health-care workers with AHC after
accidental needlestick injury, and with experimentally infected
chimpanzees revealed an enormous replicative capacity of HCV
[59–63]. Already within days after infection, high viral titers have
been measured in the serum and liver of chimpanzees. After a
very rapid initial increase, viral titers remain constant for the fol-
lowing 4–8 weeks, and then decline concomitant with the onset
of an adaptive cellular immune response in the liver and a rise
in serum transaminases [60–62,64]. The combined innate and
adaptive host-response is often strong enough to eliminate HCV
infections in chimpanzees. In humans, HCV infections become
chronic in more than half of the infected individuals.
Key Points 1
• Hepatitis C virus (HCV) has a very high replicative
capacity. Within days after infection, viral titers of 
>106 IU/ml can be measured in the serum
• The innate immune system reacts to HCV infections
with the induction of interferon (IFN) stimulated genes
in the liver. This initial type I and/or type III IFN driven
response controls viral replication to some extent, but
cannot eliminate HCV completely
• 4-8 weeks after infection, HCV specific T cells are
recruited to the liver. HCV replication is inhibited by non-
cytolytic (IFN-γ-mediated) and cytolytic mechanisms. In
about 30% of the patients, the immune reaction during
acute hepatitis C is strong enough to eliminate HCV
infection
• In the acute phase of the infection, HCV is highly 
vulnerable to therapy with recombinant IFN-α. 
Over 90% of the patients can be cured with IFN-α 
monotherapyInduction of interferon by hepatitis C virus
For the following discussion, the acute phase of HCV infection
will be subdivided into an early acute phase prior to the activa-
tion and recruitment of HCV speciﬁc T cells in the liver, and a late
acute phase characterized by the adaptive immune response
(Fig. 2). The host reaction in the liver during the early acute phase
of HCV infection has been exclusively studied in experimentally
infected chimpanzees [60–62,64]. In this animal model, a strong
host-response to HCV has been detected already days after
infection. Transcriptome analysis revealed induction of type I
IFN-stimulated genes [60,61]. The extent and duration of ISG
induction showed a positive correlation with viral load [61]. This
suggests that the most important regulator of ISG induction in
the early acute phase is the amount of HCV-derived PAMP mole-
cules that stimulate TLR dependent and/or RIG-I dependent sen-
sory pathways. The precise nature of the HCV PAMP is a matter of
debate. Several reports stress the importance of uncapped 50-
phosphate double-strand RNA, but the 30 non-translated region
of the HCV genome was also shown to induce the RIG-I pathway
[65–68]. However, in all these studies, in vitro transcribed RNAJournal of Hepatology 201was transfected into cells, and it is unknown if any of these RNA
molecules are exposed to sensory pathways in HCV infected cells.
Indeed, infection of RIG-I competent HuH7 cells with HCV does
not stimulate the RIG-I pathway at all [69,70]. There have been
several recent papers showing IFN induction in primary human
hepatocytes (PHH) infected with HCV [71–73], but this experi-
mental system is prone to contamination of the hepatocytes with
non-parenchymal cells that could be the source of IFN production.
It has been shown that plasmacytoid dendritic cells (pDCs) can
produce large amounts of IFN-a when co-cultured with HCV rep-
licon cells [74]. Therefore, it is conceivable that relatively few
pDCs present in PHH cultures could be the source of IFNs pro-
duced after infection with HCV. Only experiments that directly
visualize IFN mRNA in situ will clarify this issue.
There is another, indirect argument in favor of models that
place IFN production in non-infected cells such as pDCs. It has
been shown that the viral protease NS3/4A very efﬁciently blocks
the activation of IRF3, a transcription factor that is essential for
IFN induction [75]. NS3/4A interferes with both the TLR depen-
dent and the cytosolic sensory pathways. NS3/4A cleaves and
inactivates MAVS, an essential component of the RIG-I pathway
[22], and TRIF, an adaptor in the TLR3 pathway [76]. It has not
been investigated whether cleavage of MAVS or TRIF3 occurs in
the early acute phase of HCV infection. In the chronic phase of
HCV infection, cleavage of MAVS was detected in 62 out of 129
(48%) liver biopsies from patients with CHC [77]. MAVS cleavage
most likely occurs in HCV infected hepatocytes, and could pre-
vent IFN induction in those cells. IFN production in non-infected
non-parenchymal cells such as pDCs would not be affected by
cleavage of MAVS or TRIF.
It has to be stressed that all those arguments for or against
hepatocytes vs. non-parenchymal cells as the source of IFN in
early AHC rely on cell culture experiments that might not reﬂect
the host-virus interactions in vivo. The clariﬁcation of the cellular
source of IFN in the early acute phase of HCV will require in situ
detection of IFN mRNA in liver biopsies of experimentally
infected chimpanzees. Technical progress is also required to iden-
tify the type(s) of IFN responsible for the induction of ISGs. Stud-
ies with chimpanzees failed to detect induction of IFNs in early
AHC [60,61]. More recent studies detected upregulation of mRNA
of type III (but not type I) IFNs in liver biopsies [72,73], and an
increase of type III IFN protein, primarily IFN-k1 (IL29), in the
serum of chimpanzees [73]. IFN-k1 serum concentrations in 6
experimentally infected chimpanzees were in the range of
200 pg/ml during the ﬁrst weeks of infection. In this early phase
of AHC, all animals had a signiﬁcant upregulation of ISGs in the
liver. However, IFN-k1 serum concentrations in the same range
have been measured in healthy (not HCV infected) humans with
presumably uninduced ISGs in the liver [78]. It is also not clear
how well human hepatocytes respond to type III IFNs. Compared
to IFN-a, IFN-ks are very weak activators of STAT1 phosphoryla-
tion in PHHs (Francois Duong and Markus Heim, unpublished).
Finally, in vivo data on the effects of IFN-k in the liver are com-
pletely missing. Therefore, the functional relevance of the
observed induction of type III IFNs in early AHC remains
speculative.Antiviral efﬁcacy of the early innate immune response
After a very rapid increase in the ﬁrst days (to weeks) after infec-
tion, HCV viral loads remain stable for several weeks, until the3 vol. 58 j 564–574 567
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emergence of the cellular immune response in the liver [60–
62,64]. ISGs are strongly induced during this entire period, but
this innate immune response is obviously not capable of clearing
HCV infections. As discussed below, several potential mecha-
nisms of viral interference with the IFN system have been
explored, and there is mounting evidence that HCV inhibits the
expression of functional antiviral effector proteins in infected
cells. The co-existence of high viral loads and high ISG expression
has been interpreted as proof that the innate IFN response is
completely ineffective against HCV. However, the short duration
of exponential increase of viral loads and the following perma-
nent restriction of the viral load during the early phase of AHC
could reﬂect an important role of the innate immune system in
the containment of HCV.
Cellular immune responses in the late phase of acute hepatitis C
The late phase of AHC begins 6–10 weeks after infection and is
characterized by the recruitment of HCV speciﬁc T cells. It lasts
2–6 weeks, is clinically characterized by elevated transaminases
and sometimes icterus, and leads to clearance of the infection
in about 30% of infected individuals. Portal and lobular CD8+ T
cell inﬁltrates are, indeed much more prominent than in CHC
[28], and several groups have shown that spontaneous elimina-
tion of HCV is associated with vigorous virus-speciﬁc CD8+ T cell
responses targeting multiple epitopes (reviewed in [79]). CD8+ T
cells inhibit viral replication through lysis of infected cells and,
more importantly, through IFN-c mediated non-cytolytic mecha-
nisms [80]. Indeed, a recently published transcriptome analysis of
liver biopsies of patients with AHC revealed a strong induction of
IFN-c stimulated genes [28]. Why does this IFN-c-dominated
response succeed in eliminating the virus in a considerable pro-
portion of patients, whereas the activation of the type I or III
IFN system in the early phase of AHC invariably fails? The num-
ber of ISGs and the expression level of ISGs seem not to be signif-
icantly different in the early vs. late phase of AHC. Is there an
important qualitative difference in ISG induction? CD8+ T cell-
derived IFN-c could stimulate the induction of a speciﬁc subset
of genes that are crucial for HCV elimination. It is also conceiv-
able that IFNs alone are not sufﬁcient and that the cellular
immune response provides additional antiviral effector systems.
However, such explanations are contested by the over 90% suc-
cess rate of therapies with recombinant IFN-a in AHC patients.
Obviously, type I IFNs can induce all the necessary antiviral effec-
tor system in HCV infected cells. The reasons for the failure of the
innate immune system in early AHC remain unknown.
The infection period following the late phase of AHC, i.e., the
early phase of CHC, has been studied only in chimpanzees. In ani-
mals that fail to clear HCV, viral load increases again after a tran-
sient decline in late AHC, and usually stabilizes at titers that are
about 10 times lower than in the early phase of AHC [62]. Con-
comitantly, type I or III ISGs are again induced [81].Interferon-stimulated gene expression in chronic hepatitis C
In humans who develop chronic infections, ISG induction varies
considerably between individuals. In about half of the patients
of Caucasian ethnicity, hundreds of type I or III ISGs are con-
stantly expressed at high levels in the liver, whereas the other
half has no detectable induction of the innate immune system.568 Journal of Hepatology 201Apart from a strong association of the minor allele of the IL28B
genotype with ISG induction [82–84], little is known about the
factors that determine the activation level of the IFN system.
Interindividual variability of MAVS cleavage by NS3/4A is proba-
bly involved. In liver biopsies of patients with CHC, the degree of
MAVS cleavage inversely correlates with ISG expression, but the
correlation is rather weak [77]. There are no systematic longitu-
dinal observation studies, but our own unpublished observations
revealed little variation of ISG expression levels between liver
biopsies obtained from the same patients at different time points
during CHC. Most likely, the extent of ISG induction remains
rather stable over decades in a given patient with CHC.
Key Points 2
• In chronic hepatitis C (CHC), HCV escapes both innate
and adaptive immunity by yet unknown mechanisms
• In a substantial proportion of patients, HCV infection
induces an IFN-mediated innate immune response
in the liver. The type of IFN (α, β, λ) responsible 
for continuous stimulation of IFN-stimulated gene 
expression and the cells that produce the relevant IFNs
have not yet been identified
• Induction of the endogenous IFN system in the liver is
not only ineffective in clearing viral infection, but also
prevents response to therapies with pegylated IFN-α
and ribavirinAntiviral efﬁcacy of the endogenous IFN system in chronic hepatitis C
The induction of the endogenous IFN system in the liver appar-
ently has little antiviral efﬁcacy. HCV persists for decades despite
the expression of hundreds of ISGs [29,85,86]. Furthermore, there
is no signiﬁcant correlation between serum or intrahepatic viral
loads with ISG expression levels [77]. Several mechanisms of viral
interference with the hepatic IFN system are conceivable. (1) HCV
could inhibit IFN-induced signal transduction through the Jak-
STAT pathway. Indeed, experimental expression of HCV proteins
in cells inhibits binding of activated STATs to IFN response ele-
ments [87]. Inhibition of Jak-STAT signal transduction was also
observed in HCV transgenic mice [88], and in liver biopsy extracts
from patients with CHC [89]. According to this ﬁrst model, tran-
scriptional induction of ISGs would occur only in uninfected
hepatocytes, and would therefore have no effect on overall viral
replication. (2) HCV could inhibit cap-dependent protein transla-
tion at the ribosomes. As a matter of fact, most reports on ISG
induction in CHC relied on quantiﬁcation of ISG mRNA expression
levels [29,85,86]. In cell culture experiments, HCV infection trig-
gers phosphorylation and activation of the RNA-dependent pro-
tein kinase PKR, which phosphorylates eukaryotic translation
initiation factor eIF2a [90]. Because phosphorylated eIF2a inhibits
cap-dependent translation, no proteins are produced from ISG
mRNAs. Of note, HCV protein production is not impaired, because
HCV RNA translation occurs through an internal ribosomal entry
site (IRES) dependent mechanism that is not impaired by
phosphorylated eIF2a [90]. This model is also supported by a
recently published ISG overexpression screen that has identiﬁed3 vol. 58 j 564–574
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Fig. 3. Treatment of chronic hepatitis C with PegIFN-a and ribavirin. Patients
with an activated endogenous IFN system have hundreds of ISGs upregulated
already before treatment (light green). Application of PegIFN-a does not further
increase ISG expression in the liver and continuous treatment with PegIFN-a and
ribavirin rarely achieves a sustained virological response (light red line). Patients
without a pre-activated IFN system show a massive induction of ISGs within 4 h
after administration of PegIFN-a (dark green), and have a high chance of being
cured by PegIFN-a/ribavirin therapy (dark red line). Adapted from Ref. [116], with
permission from Elsevier.
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translational inhibition as the key antiviral effector mechanism of
numerous ISGs [91]. According to this second model, ISG mRNA
expression would occur in both un-infected and infected hepato-
cytes, but ISG protein production only in un-infected cells. (3)
HCV does not interfere with ISG transcription or translation. Both
mRNAs and proteins of ISGs would be induced, but HCV replica-
tion occurs in subcellular compartments that are not accessible to
antiviral proteins induced by IFNs. Presently, there is little exper-
imental evidence to support the third model. (4) HCV does not
interfere with ISG protein production (same as in the third model),
but HCV proteins inhibit antiviral effector functions apart from
translational inhibition. Indeed, it has been recently shown that
USP18, a classical ISG, can be strongly expressed in all hepatocytes
in liver biopsies from patients with CHC and an induced endoge-
nous IFN system [28]. If conﬁrmed with other ISGs, such uniform
expression of ISG proteins would disqualify models 1 and 2, and
favor models 3 or 4. Clearly, progress in this controversial ﬁeld will
only come with advanced imaging studies that allow detecting
HCV RNA and proteins and ISG mRNAs and proteins on a single
cell level in liver biopsies from patients with CHC.
Non-response to PegIFN-a in CHC patients with an activated
endogenous IFN system in the liver
It is now ﬁrmly established that patients with an activated
endogenous IFN system are poor responders to IFN-a-based ther-
apies [29,85,86,92]. Analysis of paired liver biopsies obtained
before treatment and 4 h after the ﬁrst injection of PegIFN-a2
revealed that patients with an activated endogenous IFN system
had hundreds of ISGs expressed at high levels already before
treatment, and that PegIFN-a2 did not further increase the
expression of these genes, i.e., was completely ineffective in the
liver [29] (Fig. 3). In such biopsies, staining for the phosphory-
lated (activated) form of STAT1 revealed a faint staining in nuclei
of hepatocytes in pretreatment biopsies, and no further increase
of phosphoSTAT1 signals 4 h after PegIFN-a injections [29]. In
contrast, no phosphoSTAT1 signals were detected in pretreat-
ment biopsies of ‘‘responder’’ patients without constitutive
induction of ISGs, but PegIFN-a injections induced a very promi-
nent and strong activation and nuclear translocation within 4 h
[29]. The reason for the apparent refractoriness of IFN-a-induced
Jak-STAT signaling is not entirely clear, but there is evidence that
USP18 is an important factor. USP18 was strongly expressed in a
large number of hepatocytes in liver biopsies from patients with
CHC and a pre-activated endogenous IFN system [28]. Moreover,
there is convincing genetic evidence from knock-out mice exper-
iments that USP18 is responsible for the long-term refractoriness
of IFN-a signaling in the liver [55]. These observations generate
an apparent paradox: since USP18 is not constitutively expressed
in cells, but is only expressed after IFN stimulation, how then can
its expression level be maintained at high levels despite complete
refractoriness of IFN-a signaling? Or in more general terms: How
can an IFN-a-induced negative regulator of IFN-a signaling be
persistently induced?
The driving force of ISG expression in CHC
The subtype(s) of IFN that drive the permanent expression of ISGs
in CHC have not been identiﬁed, and little is known about the cel-
lular source of IFN(s) too. Expression of mRNA of IFN-as, IFN-b,
IFN-c has not been consistently detected in liver biopsies fromJournal of Hepatology 201patients with CHC, even in samples with very high expression
of ISG mRNAs. IFN-c can be further excluded as driver of ISG
expression in CHC because the set of ISGs induced in CHC con-
tains typical type I IFN-stimulated genes, but not type II-induced
ISGs [28,29,81]. IFN-as can be tentatively excluded because IFN-a
signaling is subject to strong negative feedback inhibition, specif-
ically by USP18, that would prevent long-lasting activation of
ISGs [28,51,55]. One could only argue that the refractory state
caused by USP18 is leaky and allows low-level STAT1 activation
below the detection limit of phosphoSTAT1 Western blots or
immunostaining techniques. However, there are more appealing
alternative explanations. Interestingly, USP18 does not inhibit
IFN-b signaling through the same receptor-kinase complex used
by IFN-as, and it does not inhibit IFN-k signaling either [56]. Con-
trary to all other IFN subtypes, IFN-k1, -k2, and -k3 mRNA can be
detected in liver biopsies [82]. Admittedly, it is presently
unknown if the low amount of mRNA detected produces enough
bio-active protein to explain the strong induction of ISGs in CHC.
No IFN proteins have been detected so far in liver biopsies of
patients with CHC. However, considering the fact that IFN-k sig-
naling is not refractory, IFN-ks remain strong candidates as driv-
ers of constitutive ISG induction in CHC patients with an
activated endogenous IFN system.
Given the difﬁculties in identifying the subtype(s) of IFN
responsible for the long-lasting induction of ISGs in CHC, it is
not surprising that the cellular source(s) are not known. IFNs
could be produced in HCV infected hepatocytes, but also in
non-parenchymal cells such as pDCs.
IL28B genotype and innate immune responses to hepatitis C virus
The recent discovery of a strong association of genetic variants of
the IL28B gene with response to PegIFN-a2/ribavirin combination
treatment of CHC and with spontaneous clearance of HCV has
been a major step towards a better understanding of the genetic3 vol. 58 j 564–574 569
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factors that control natural history, host-virus interactions and
IFN responsiveness in individual patients [93–97]. The associa-
tion was discovered by genome-wide association studies (GWAS).
GWAS make use of the ever-improving efforts to map the human
genome to associate complex traits or disease outcome with
inherited genetic variations. Single nucleotide polymorphisms
(SNPs) are variations of one nucleotide in a genetic sequence.
Common SNPs are deﬁned as having a minor allele frequency of
greater than 5%. An estimated 10 million common SNPs exist
and are transmitted from generation to generation, often in
blocks, allowing a few particular, or tag SNPs to be representative
of a block (haplotype) [98]. Three SNPs close to the IL28B gene
were found to be most strongly associated with response to Peg-
IFN-a/ribavirin in patients with CHC: rs12979860 [93],
rs8099917 [94,99,100] and rs12980275 [100]. rs12979860 is
3176 base pairs upstream (50) of the IL28B gene, rs8099917 is
7554 base pairs upstream of the IL28B gene, and rs12980275 is
2488 base pairs downstream (30) of the IL28B gene (Fig. 4). SNP
rs12979860 detects a single nucleotide variation at position
39,738,787 of human chromosome 19. The major allele has a
cytosine at this position, and the minor allele a thymine. Accord-
ingly, the major and minor alleles are designated C allele and T
allele, respectively. An individual patient can be homozygous
for the C allele (C/C genotype), heterozygous (C/T genotype) or
homozygous for the T allele (T/T genotype). For rs8099917 and
rs12980275, the major/minor alleles are the T/G and A/G,
respectively.
Key Points 3
• Genetic variants near the interleukin 28B (IL28B) gene
are strongly associated with spontaneous clearance of
HCV and with response to therapy with pegylated IFN-α
and ribavirin
• The minor alleles (associated with poor response to
therapy) are positively associated with IFN-stimulated
gene expression in CHC
• The molecular mechanisms that link genetic variants
near the IL28B gene to constitutive activation of the
endogenous IFN system in the liver are presently 
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Fig. 4. IL28B gene locus on human chromosome 19. The 3 most strongly
associated SNPs are in the genome regions ﬂanking the IL28B gene. Nucleotide
numbers on chromosome 19 are indicated for three SNPs and for the start of the
coding region of the IL28A and IL28B gene.
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The ﬁrst published GWAS by Ge et al. reported a strong positive
correlation of the C allele of rs12979860 with response to Peg-
IFN-a/ribavirin treatment in patients with HCV genotype 1 infec-
tions [93]. In patients of European ancestry, the sustained
virological response rate (SVR) was approximately 80% in
patients with the C/C genotype, around 40% in patients with
the C/T genotype, and around 35% in T/T patients. In African-
Americans, SVR was lower in all genotypes compared to Euro-
pean-Americans, but the differences between IL28B genotypes
were maintained. Interestingly, the allele frequencies of the
major and minor rs12979860 variants show a wide variation
between East Asians, European-Americans, Hispanics, and Afri-
can-Americans [93]. In East Asians, the frequency of the major
allele (C allele) was over 90%, in European-Americans and His-
panics around 70%, and in African-Americans around 40%. These
ﬁndings correlate very well with the overall response rate to Peg-
IFN-a/ribavirin treatments in the different groups, where East
Asians have SVR rates of more than 70%, European-Americans
and Hispanics around 50%, and African-Americans around 25%
[93]. As mentioned above, additional SNPs near the IL28B gene
were found to be associated with SVR in large patients’ cohorts
from Europe, Australia, and Japan [94,96,97]. The two most
widely investigated SNPs, rs12979860, and rs8099917, are in
strong linkage disequilibrium and are similarly informative.
Spontaneous clearance of HCV infection
The major alleles of the IL28B SNPs are not only associated with
better response to treatment with PegIFN-a/ribavirin, but also
with spontaneous clearance of HCV infections [94,95,101]. Spon-
taneous clearance is rare in the chronic phase of HCV infection,
but occurs in 20–40% of the patients with AHC. The rate of spon-
taneous clearance varies according to IL28B genotypes: in
patients with the rs12979860 C/C genotype, spontaneous clear-
ance occurs in 50–60% of cases, compared to only 10–20% in
the C/T and T/T group [95,101].
Molecular mechanism
The molecular mechanisms that link the genetic variants near the
IL28B gene to spontaneous and PegIFN-a/ribavirin-induced clear-
ance of HCV remain largely unknown. Since the IL28B genes
encodes IFN-k3, the most obvious explanations center on muta-
tions in the promoter or the coding region of IFN-k3. However,
no such mutations have been identiﬁed despite extensive
analysis.
There is a signiﬁcant association between IL28B genotypes and
ISG expression in pretreatment liver biopsies [82–84]. The activa-
tion of the endogenous IFN system in the liver is signiﬁcantly
more frequent in patients with one or two minor alleles. This
could be elegantly explained by an increased IL28B gene expres-
sion from the minor allele. However, two studies reported the
opposite, i.e., less intrahepatic IL28B expression in patients with
the minor allele genotype [82,102]. Furthermore, serum levels
IFN-k1 (IL29) and IFN-k2/3 were reported to be lower in carriers
of the minor allele [78]. Finally, a stratiﬁcation of patients accord-
ing to response to treatment and IL28B genotype revealed that
hepatic ISG expression correlates with treatment response3 vol. 58 j 564–574
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irrespective of the IL28B genotype [82]. Therefore, IFN-k does not
seem to directly control the level of ISG induction.
In conclusion, the molecular mechanism linking IL28B geno-
type to treatment response remains to be elucidated. Interesting
insights recently came from studies looking at treatment
responses in patients with CHC that had received liver trans-
plants. Liver grafts are universally reinfected, and post-transplant
HCV infections often have a more severe course with rapidly pro-
gressive ﬁbrosis. Recipients with the unfavorable IL28B
rs12979860 T allele are at risk for more severe HCV recurrence
and more rapid ﬁbrosis progression [103,104]. Surprisingly,
donor genotypes had the opposite effect: donor rs12979860 C/C
genotype favored inﬂammation and ﬁbrosis [103,104]. Similarly,
the response to treatment with PegIFN-a/ribavirin in liver trans-
planted patients with CHC is also associated with the IL28B geno-
type of both the donor and the recipient [102,105–108]. This
ﬁnding demonstrates that the molecular mechanism linking the
IL28B genotype to response to treatment involves both the
immune system or other organs in the body (the ‘‘recipient’’) as
well as the resident liver cells (the ‘‘donor’’). How this mutual
crosstalk between recipient and donor cells is dependent on the
IL28B genotype in both cell types remains entirely unclear.Conclusion and perspectives
The study of host virus interactions in HCV infections has not
only increased our understanding of the pathogenesis of one of
the most important liver diseases worldwide, but has also made
important contributions in basic innate immunity and immuno-
biology of chronic viral infections in general. The IFN system pro-
vides a powerful antiviral response, and in order to establish a
persistent infection, viruses have evolved escape strategies.
HCV is no exception to that rule, but its escape strategy seems
to be unique. Most viruses inhibit either the induction of IFNs
or IFN signal transduction, thereby preventing the transcriptional
induction of antiviral genes [109]. In the early phase of infection,
HCV cannot prevent the activation of the IFN system in the liver,
at least not in experimentally infected chimpanzees. However, in
over half of the infected patients, HCV persists despite a rapid and
strong IFN response. The molecular mechanisms of escape remain
elusive. In CHC, HCV can co-exist with a permanently active
endogenous IFN system for decades. When such patients are trea-
ted with PegIFN-a and ribavirin, virological response is very rare.
Not only is the endogenous IFN system not capable of eliminating
HCV, it even inhibits response to therapeutically injected recom-
binant IFN-a. In another group of patients with CHC, HCV seems
to be largely ignored or tolerated by the immune system. Those
patients with an activated endogenous IFN system have a very
good chance to be cured by treatment with PegIFN-a and ribavi-
rin. The underlying molecular mechanisms are not known.
Refractoriness of IFN-a signaling is an important factor, and res-
toration of a full response capability of IFN signaling pathways or
circumvention of blocked signaling pathways might provide ther-
apeutic opportunities. Both in AHC and in CHC, ISG induction is
positively correlated with viral load. One of the most interesting
results from a landmark study in chimpanzees with CHC was the
ﬁnding that the inhibition of viral replication by anti-miR122
resulted in a simultaneous decline of ISG induction in the liver
[110]. It is conceivable that current triple therapies with protease
inhibitors or other direct acting antivirals achieve such highJournal of Hepatology 201virological response rates by restoring IFN sensitivity in patients
with pre-activated (refractory) IFN systems. Indeed, the ﬁnding
that the major improvements of response rates are observed in
patients with unfavorable IL28B genotypes (associated with high
ISG expression) strongly supports such a model [111–115].
Refractoriness of IFN-a signal transduction pathways could be
bypassed by PegIFN-k. As outlined above, there is experimental
evidence from cell culture and mouse experiments that IFN-b
and IFN-k signaling remains intact in presence of inhibitors of
IFN-a signaling such as USP18. This has not yet been conﬁrmed
in humans, but if the concept is correct, PegIFN-k would be espe-
cially favorable for the treatment of patients who did not respond
to previous (peg)IFN-a/ribavirin therapies.
The development of potent new direct acting antivirals opens
the perspective of IFN-free treatments for CHC, and with it, the
perspective of a declining interest of the hepatology research
community in host-virus interactions in HCV infections. How-
ever, even the best treatments should not detract efforts to
develop a preventive vaccine. A thorough understanding of
host-virus interactions is most likely a prerequisite for the
rational design of a vaccine. Furthermore, the strong association
of IL28B genotype with spontaneous clearance of HCV and
response to treatments with (and without) IFNs is a landmark
discovery in HCV (and GWAS) research. The elucidation of the
molecular mechanisms that link single nucleotide polymor-
phisms near the IL28B (IFN-k3) gene to basic host reactions, such
as spontaneous virus control, and to the response to antiviral
therapies remains one of the most interesting challenges in the
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